+34 620 10 75 37info@nanbiosis.com

Posts on Jan 1970

U28-S07. Transmission Electron Microscopy (TEM) (Onsite&Remote)

Conventional TEM provides structural information of samples prepared to electron transparency in the sub-nanometer range. Once prepared, many biological samples, including bacteria, viruses, yeasts, cells, and tissue sections can be characterized using TEM. Moreover, TEM can be used to characterize many other types of material such as substrates or nanoparticles making it a highly versatile technique.

Applications:
>> Cellular characterization
>> Tissues characterization
>> Biomaterials characterization
>> Macromolecular complexes characterization

Read More

U28-S06. Time Domain NMR (TD-NMR) (Onsite&Remote)

NMR relaxometry refers to the measurement of relaxation times, typically T1 and T2, as a function of magnetic field. This is crucial in the development of new contrast agent for MRI.

Applications:
>> Measurement of Relaxation Times (T1, T2, T2*)

Read More

U28-S05. High Resolution Magic Angle Spinning (HR-MAS) NMR (Onsite&Remote)

HR-MAS NMR is based on solid-state NMR, which uses magic-angle spinning at high speeds to average anisotropic interactions, leading to narrower widths. The moderate spin rates used in HR-MAS allows high resolution spectra to be obtained from intact tissue, i.e., without the need of any metabolite extraction procedure. HR-MAS NMR is widely used for metabolomic studies, especially in cancer research, where the metabolic profile (metaboloma) of tumor biopsies can be characterized using just few milligrams of intact tissue (tissue biopsy). HR-MAS can also be used for the structure characterization and elucidation of partially insoluble compounds.

Applications:
>> Metabolomics of intact tissue samples (tumor biopsies, …)
>> Structure Characterization and Elucidation of partially insoluble compounds)

Read More

U28-S04. High Resolution Liquid NMR (Onsite&Remote) OUTSTANDING

Liquid NMR is a fundamental tool both in chemistry and biomedicine research. Its applications to chemistry range from structure elucidation of small molecules to studies of ligand-protein interactions. In biomedicine, the use of liquid NMR has expanded from the classical metabolic studies using enriched stable isotope tracers to the more recent NMR-based metabolomics of biofluids (urine, plasma, CSF).

Applications:
>> Structure verification and elucidation
>> Molecular mobility: determination of conformation in solution
>> Determination of enantiomeric excess
>> Kinetic and temperature studies of reaction mixtures
>> Metabolomics of liquid samples (CSF, plasma, urine and tissue extracts)
>> Metabolomics of liquid samples (CSF, plasma, urine and tissue extracts)

Read More

U28-S03. Computed Tomography (CT) (Onsite&Remote)

Computerised Tomography (CT) allows high quality 3D imaging of preclinical animal models based on the reconstruction of 2D X-ray images captured at different angles. Albira uses dedicated beds for rats and mice with incorporated gas anesthesia. Different image capture modes allow users to balance capture time and image quality. The Albira software suite automates the reconstruction process, while the included PMOD software allows users to perform advance analyses and to export data into popular formats such as DICOM. It allows the possibility of combining CT data with fluorescence.

Applications:
>> Tumour imaging and quantification
>> Bone and implantation studies
>> Anatomical CT data is often used in conjunction with other modalities including fluorescence

Read More

U28-S02. Fluorescent and Bioluminescent Optical Imaging (Onsite&Remote) OUTSTANDING

The use of fluorescent and bioluminescent techniques for small animal-based studies into cancer, arthritis and heart disease have grown tremendously in recent years. Part of the Multimodal Imaging Service, Bionand offers the Carestream In-Vivo Xtreme animal imaging system which allows up to five mice to visualized simultaneously using fluorescence and bioluminence methods.

Applications:
>> Tumour and Stem Cell Tracking
>> Monitoring of Drug Delivery and Targeting
>> High throughput Pharmacodynamic studies
>> Imaging and validating new Probes and Biomarkers
>> Bionand offers a range of complimentary services including animal housing facilities, and histology, microscopy and cytometry services

Read More

U28-S01. Magnetic Resonance Imaging (MRI) (Onsite&Remote) OUTSTANDING

Magnetic Resonance Imaging (MRI) is a very versatile technique that offers not only excellent morphological information, but also functional and physiological. Furthermore, important advances during last years in the development of highly sensitive contrast agents using nanotechnology approaches have brought MRI into the molecular imaging arena. Thus, small animal MRI scanners have become a key tool in the development of magnetic nanoparticles for medical diagnosis and therapy.

Applications:
>> Anatomical Studies: tumors, inflammation, Degenerative diseases, etc.
>> Functional Studies: brain perfusion, vascular permeability, in vivo metabolic profiling, etc.
>> Pharmocokinetics and Biodistribution of new Contrast Agents (or any drug magnetically labeled)
>> Monitoring of Drug Delivery and Targeting
>> Follow up of Therapy Response

Read More

STRYKER & NANBIOSIS start a promising line of biomedical research collaboration

On January 23-24th a two-day meeting between NANBIOSIS and Stryker Trauma GmbH, took place at the Carlos III Health Institute, in Madrid, to explore synergies and potential joint initiatives.  

Nils Reimers and Robin Buescher from Stryker, presented some of their research and upcoming projects in the field of trauma medical devices, and representatives from NANBIOSIS’ units -Marisa González from U16 Surface Characterization and Calorimetry Unit, Teresa Galán from U7, Nanotechnology Unit, Gemma Pascual from U17 Confocal Microscopy Service, from CIBER-BBN, Marisa García from U28 (Bionand) and José Francisco Guillén and Francisco Sanchez Margallo from the units of the Jesús Usón Minimum Invasive Surgery Center (CCMIJU) , together with Jesús, Izco Executive Director of NANBIOSIS and Ramon Martínez, Scientific Director of CIBER-BBN- explained their technologies.

The second day, the meeting location was moved to the CCMIJU in Cáceres, to visit the Center facilities and continue conversations.

All attendees expressed their satisfaction with the development of the meeting and agreed to continue with the explorations in forthcoming meetings.

Photo caption: From left to right: José Francisco Guillén (Quality Guarantee Manager of CCMIJU),  Jesús Izco (NANBIOSIS Executive Director), Francisco Sanchez Margallo (Scientific Director of CCMIJU), Nils Reimers (Senior Manager R&D – Stryker Trauma GmbH), Robin Buescher (Director R&D Stryker Trauma GmbH), Margarita Casado (Management Staff of NANBIOSIS)”

Read More

Laura Lechuga, Scientific Director of Unit 4 of NANBIOSIS Coordinates a EuroNanoMed project

ABISENS Monitoing of Acquired Brain Injury and recovery biomarkers by the combined label-free nanosensing of multiple circulating molecules is one of the project awarded in the EuroNanoMed III joint call, will be coordinated by Laura Lechuga through the CIBER-BBN

Abisens will employ the Unit 4 of Nanbiosis, Biodeposition and Biodetection Unit or the multiplexed biofunctionalization of the biosensor chips and their methodology optimisation

The evaluation of patients after brain injuries, which produces severe impairments, remains a major unmet clinical need. Nowadays the diagnosis, prognosis and the efficacy of rehabilitation treatments are mainly assessed by clinical examinations, neuroimaging and electrophysiological tests during a long hospitalization stay. The aim the project is to offer as an alternative a new nanobiosensor platform able to identify and quantify multiple brain biomarkers in blood with high sensitivity and in a short time. The new biosensor platform will employ nanophotonic waveguide circuits in combination with oligonucleotide chemistry.

The project will be characterized by a strong interdisciplinary and translational nature resulting from the meeting between real clinical needs and high-level technological integration of biosensing and bimolecular aspects.

Read More

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day

Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths.

Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%.

The only way to understand cancer and, someday, eradicate it or eliminate the suffering and death due to this disease, is RESEARCH

NANBIOSIS as an ICTS (Singular Scientific and Technical Infrastructures) for biomedical research plays a very important role in the fight against cancer. Some examples are bellow:

Thanks to a coordinated action between units U1 of Protein Production Platform (PPP), U18 of Nanotoxicology and U29 of Nucleic Acid Synthesis, NANBIOSIS is developing nanopharmaceuticals with a high degree of efficacy for the treatment of metastases in colon cancer, by using of proteins with high specificity of binding to metastatic cells and a high degree of permanence in the blood flow, loaded with anti-cancer drugs that are selectively released inside the tumor cells that are going to form the metastases. Through the public financing of a NEOTEC project and a RETOS-COLABORACION and the company NANOLIGENT SL, the first antimetastatic drug on the market will be developed.

The Protein Production Platform-PPP collaborates with research projects whose objective is the development of new cancer therapies based on recombinant modular proteins with the ability to self-assemble. These multimeric complexes have shown, in animal models, a high stability in serum and an improved biodistribution compared to that observed with drugs for clinical use. These principles have been valued in different types of cancer, including colorectal cancer and breast cancer. The modular design of these constructions allows the incorporation or substitution of direct peptides and therefore they are presented as a transversal tool for more effective treatments against cancer. In addition, the PPP has served the Vall d’Hebron Institute of Oncology (VHIO) of Barcelona, the Josep Vilanueva group (CIBERONC) in the field of biomarker study and new targets associated with triple negative breast cancer (TNBC).

Unit 6 of NANBIOSIS Biomaterial Processing and Nanostructuring Unit is working on a project in collaboration with VHIR, financed by the Spanish Goverment and CIBER-BBN, for the development of a new nanomedicine for the treatment of high-risk neuroblastoma, one of the most frequent childhood cancers.

Unit 6 is also working on the project Artificial Lymph Nodes for Cancer ImmunoTherapy (ALYCIA) A project born of a initiative of CIBER-BBN/ CIBERONC to enhance scientific interdisciplinary collaborations between research groups working on oncology and nanomedicine. Researchers of unit 6 will develop Artificial Lymph Nodes (ALN) based on dynamic 3D scaffolds able to promote efficient ex vivo lymphatic cell expansion of relevant phenotypes. Such ALN represent a new approach to lymphocyte expansion, which not only includes artificial Antigen Presenting Cells in suspension like the state-of-the-art expansion techniques, but also mimics the function of the LN ex vivo.

One of the singular capabilities of the U25 of NANBIOSIS NMR: Biomedical Applications I is the acquisition of high quality, high resolution preclinical magnetic resonance imaging/spectroscopy/spectroscopic imaging data. This allows performing leading-edge studies in preclinical cancer models such as noninvasive therapy response follow-up in murine brain tumours, revealing new response biomarkers with translational potential for brain cancer patients.

NANBIOSIS U4 Biodeposition and Biodetection Unit  is currently developing the national project PREDICT Point-of-care Nanoplasmonic Platforms for Novel High-Value Diagnostics and Therapy Follow-Up , which works in the early detection of lung cancer. PREDICT project will use the Unit 4 of Nanbiosis for the multiplexed biofunctionalization of the biosensor chips and their methodology optimisation.

Finally, Unit 20 of NANBIOSIS In Vivo Experimental Platform at VHIR, is the most implicated of the CIBER units on projects in the field of cancer, just to name some of them: H2020-NoCanTher: magnetic nanoparticles against pancreatic cancer through the use of hyperthermia combined with conventional treatment. H2020-Target-4-Cancer: nanotherapy based on polymeric micelles directed against specific receptors of tumor stem cells in colorectal cancer. H2020-DiamStar: nanodiamonds directed against leukemia for the potentiation of chemotherapy. FET-OPEN EvoNano: in silico and tumor-tumor models for the prediction of PK / PD and tumor efficacy of antitumor nanomedicines against tumor stem cells. FIS-ISCIII: polymeric micelles for siRNA and combined therapy against breast cancer tumor stem cells. CarboXigel: hydrogels for the sustained release of chemotherapeutic drugs against the metastatic spread of ovarian cancer. MelanoMir: nanomedicine applied to skin cancer, melanoma, beside other projects promoted by CIBER-BBN.

Read More